Categories
Diabetes Obesity & Metabolism HCRU

Healthcare resource utilization and related financial costs associated with glucose lowering with either exenatide or basal insulin: A retrospective cohort study

Holden S E, Morgan C L, Qiao Q, Jenkins-Jones S, Berni E R, Currie C J. 20 Feb 2017

Categories
Diabetes Diabetes Obesity & Metabolism

Glucose-lowering with exogenous insulin monotherapy in type 2 diabetes: dose association with all-cause mortality, cardiovascular events and cancer

Holden S E, Jenkins-Jones S, Morgan C L, Schernthaner G, Currie C J. 14 Nov 2014

Categories
Diabetes Obesity & Metabolism

Mortality Risk with Sulphonylureas Compared to Metformin

Holden S E, Currie C J. 18 Feb 2014

Categories
Diabetes Obesity & Metabolism

Can people with type 2 diabetes live longer than those without? A comparison of mortality in people initiated with metformin or sulphonylurea monotherapy and matched, non-diabetic controls

Bannister Ch A, Holden S E, Jenkins-Jones S, Morgan C L, Halcox J P, Schernthaner G, Mukherjee J, Currie C J. 07 Jul 2014

Categories
Diabetes Obesity & Metabolism

Optimizing clinical outcomes resulting from glucose-lowering therapies in type 2 diabetes: increased confidence about the DPP-4 inhibitors and continued concerns regarding sulphonylureas and exogenous insulin

Currie C J, Holden S E. 07 Jul 2014

Categories
Diabetes Obesity & Metabolism

Combination therapy with metformin plus sulphonylureas versus metformin plus DPP-4 inhibitors: association with major adverse cardiovascular events and all-cause mortality

Morgan C L, Mukherjee J, Jenkins-Jones S, Holden S E, Currie C J. 22 May 2014

Categories
Diabetes Obesity & Metabolism

Association between first-line monotherapy with sulphonylurea versus metformin and risk of all-cause mortality and cardiovascular events: a retrospective, observational study

Morgan C L, Mukherjee J, Jenkins-Jones S, Holden S E, Currie C J. 11 Apr 2014

Categories
Diabetes Obesity & Metabolism

How many people inject insulin? UK estimates from 1991 to 2010

S. E. Holden, E. A. M. Gale, S. Jenkins-Jones, C. J. Currie. 10 Jan 2014

Categories
Diabetes Obesity & Metabolism

The incidence of type 2 diabetes in the United Kingdom from 1991 to 2010

Holden S E, Barnett A H, Peters J R, Jenkins-Jones S, Poole C D, Morgan C L, Currie C J. 15 May 2013

Categories
Diabetes Obesity & Metabolism

Weight change in people with type 2 diabetes: secular trends and the impact of alternative antihyperglycaemic drugs

Morgan C L, Jenkins-Jones S, Evans M, Barnett A H, Poole C D, Currie C J. 22 Dec 2011

We use cookies to give you the best online experience. By agreeing you accept the use of cookies in accordance with our cookie policy.

Privacy Settings saved!
Privacy Settings

When you visit any web site, it may store or retrieve information on your browser, mostly in the form of cookies. Control your personal Cookie Services here.

These cookies are necessary for the website to function and cannot be switched off in our systems.

In order to use this website we use the following technically required cookies
  • wordpress_test_cookie
  • wordpress_logged_in_
  • wordpress_sec

Decline all Services
Accept all Services

MEET OUR BRANDS

About HDS

  • Our company
  • Boilerplate copy

HUMAN DATA SCIENCE

Logo
  • The HDS Logo
  • Logo mark
  • Clearspace
  • Backgrounds
Colours
  • Primary Palette
  • Secondary Palette

LIVINGSTONEIQ

Logo
  • The Livingstone Logo
  • Logo mark
  • Clearspace
  • Backgrounds
Colours
  • Primary Palette
  • Secondary Palette

PREVALENCEUK

Logo
  • The PrevalenceUK Logo
  • Logo mark
  • Clearspace
  • Backgrounds
Colours
  • Primary Palette
  • Secondary Palette

TYPOGRAPHY

  • Typestack

VOICE AND TONE

ICONS

  • Icon basics
  • Design considerations
  • Icon styles